Research Overview
Peptides for Belly Fat
A research overview of peptides that have been studied in the context of abdominal adiposity and central fat accumulation.
Belly fat, particularly visceral adipose tissue surrounding internal organs, has distinct metabolic implications. Several peptide-based therapies target pathways involved in abdominal fat reduction.
What This Page Covers
This page examines peptides investigated for reducing abdominal fat deposits. Abdominal adiposity is associated with increased metabolic risk independent of overall body weight. The peptides covered range from FDA-approved GLP-1 receptor agonists that have demonstrated reductions in waist circumference in clinical trials, to growth hormone-related peptides specifically studied for their effects on truncal fat distribution. Evidence quality varies substantially across these compounds.
How These Peptides May Address Belly Fat
Mechanism 01
Growth Hormone Axis Modulation
Tesamorelin directly stimulates growth hormone release, which has been shown to preferentially reduce visceral adipose tissue. This mechanism is specific to the GH pathway and is distinct from appetite suppression.
Mechanism 02
Incretin-Mediated Appetite Suppression
GLP-1 receptor agonists reduce overall body weight through appetite regulation and delayed gastric emptying, with secondary reductions in abdominal fat observed in clinical trials.
Mechanism 03
GH-Fragment Lipolysis
AOD-9604 is a modified fragment of human growth hormone designed to isolate its lipolytic properties. While theoretically targeting fat metabolism, human trial results have been largely disappointing.
Peptides Commonly Discussed for Belly Fat
Ordered by evidence level.
Tesamorelin
FDA ApprovedGHRH agonism
Growth hormone releasing hormone analog FDA-approved to reduce excess abdominal fat in HIV-associated lipodystrophy (Egrifta).
Semaglutide
FDA ApprovedGLP-1 receptor agonism
GLP-1 receptor agonist FDA-approved for weight management. Clinical trials show significant reductions in waist circumference alongside overall weight loss.
Tirzepatide
FDA ApprovedDual GIP/GLP-1 agonism
Dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management, with demonstrated reductions in abdominal fat in trial populations.
AOD-9604
Animal StudiesGH-fragment fat metabolism
Modified growth hormone fragment researched for fat metabolism effects. Failed to meet primary endpoints in controlled human obesity trials.
Quick Comparison
| Peptide | Primary Mechanism | Evidence | Research Context |
|---|---|---|---|
| Tesamorelin | GHRH agonism | FDA Approved | FDA-approved for HIV lipodystrophy; RCTs demonstrate visceral fat reduction |
| Semaglutide | GLP-1 receptor agonism | FDA Approved | Multiple large RCTs; FDA-approved for obesity |
| Tirzepatide | Dual GIP/GLP-1 agonism | FDA Approved | Multiple large RCTs; FDA-approved |
| AOD-9604 | GH-fragment fat metabolism | Animal Studies | Phase 2 trials completed; not approved; failed primary endpoints |
What the Research Suggests
Best Evidence for Belly Fat
The strongest evidence for abdominal fat reduction comes from FDA-approved therapies. Tesamorelin has specific approval for visceral fat reduction in HIV lipodystrophy, while GLP-1 agonists demonstrate abdominal fat loss as part of overall weight reduction. GH-fragment peptides have not demonstrated convincing efficacy.
Strongest Individual Compound
Tesamorelin for visceral adipose tissue reduction in its approved indication. Semaglutide and tirzepatide for overall body weight reduction with secondary abdominal fat loss in obesity populations.
What This Category Cannot Do
Tesamorelin's approval is limited to HIV-associated lipodystrophy. Its use for general belly fat reduction is off-label and less studied. GLP-1 agonists reduce belly fat as part of systemic weight loss, not through targeted abdominal mechanisms. AOD-9604 failed human trials.
PSI Reading of the Evidence Gap
Belly fat reduction research on PSI covers two distinct evidence tiers. Tesamorelin has FDA approval for visceral fat reduction in HIV-associated lipodystrophy with controlled trial data in that specific population. Semaglutide and tirzepatide demonstrate abdominal fat reduction as part of overall weight loss in large phase 3 programs. GH-fragment compounds have not demonstrated clinical efficacy for abdominal fat reduction in controlled human trials. These represent meaningfully different evidence bases for the same outcome.
How to Choose
Research-informed guidance for peptides studied in the context of belly fat. Not a recommendation.
Want FDA-approved therapy specifically shown to reduce visceral fat
Tesamorelin (approved for HIV lipodystrophy only)
Want strongest overall weight loss evidence including abdominal fat
Semaglutide or Tirzepatide
Interested in GH-fragment research despite negative trial outcomes
AOD-9604 (note: failed human trials)
Regulatory Status
3 compound(s) FDA-approved for related indications. 1 available through compounding.
Important Limitations
FDA-Approved
- Tesamorelin (Egrifta): HIV lipodystrophy
- Semaglutide (Wegovy): obesity
- Tirzepatide (Zepbound): weight management
Research-Only
- AOD-9604: failed human trials, not approved
Key Considerations
FDA-approved GLP-1 agonists carry known GI side effects. Tesamorelin may affect glucose metabolism. Research peptides lack established safety profiles.
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, not general abdominal fat reduction.
GLP-1 agonists reduce belly fat as part of systemic weight loss. They do not specifically target abdominal adipose tissue.
AOD-9604 failed to meet primary endpoints in controlled human obesity trials and is not approved for any clinical use.
No peptide has been approved specifically for cosmetic belly fat reduction in the general population.
Explore More
Related Hubs
Who This May Apply To
Individuals with centrally distributed adiposity seeking to understand which peptide therapies have clinical evidence for abdominal fat reduction.
Healthcare providers evaluating the evidence base for peptide-based approaches to truncal obesity.
Researchers comparing GH-axis and incretin-based mechanisms for visceral fat modulation.
Related Conditions
This page is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The peptides discussed include both FDA-approved medications and research compounds that are not approved for clinical use. Always consult a qualified healthcare professional before making any decisions about medical treatments. The Peptide Science Institute is an independent research database and does not sell, prescribe, or recommend any compounds.